Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
ShangBay Capital is a venture capital firm established in 2015 and headquartered in Palo Alto, California. The firm focuses on investments in the medical device, biotechnology, and healthcare technology sectors. ShangBay Capital was founded with the mission of addressing significant unmet clinical needs through innovative solutions that improve patient outcomes.
Currently, ShangBay Capital manages a portfolio of over 75 companies, demonstrating its active engagement in the healthcare sector. The firm has built a reputation for its collaborative approach with entrepreneurs, leveraging its extensive network to support the commercialization of products and the growth of startups. Notable milestones include successful exits from companies such as Lucira Health and Arrinex, showcasing the firm’s ability to identify and nurture high-potential investments.
ShangBay Capital's geographic focus spans North America and global markets, allowing it to tap into diverse opportunities within the healthcare landscape. The firm’s deep understanding of market dynamics in the medical device industry positions it as a valuable partner for startups aiming to innovate in this space.
ShangBay Capital invests primarily in medical devices, biopharma, and healthcare technologies that demonstrate clinical benefits for unmet needs. The firm targets early-stage opportunities, emphasizing a collaborative approach with entrepreneurs to facilitate product commercialization and startup growth. ShangBay Capital seeks to partner with founders who are committed to addressing significant healthcare challenges through innovative solutions.
The firm’s investment strategy is characterized by a focus on sectors that include biotechnology, healthcare technology, and medical devices. ShangBay Capital typically engages in investments that range from seed to Series A stages, providing check sizes that align with the needs of early-stage companies. The firm’s extensive network and deep market insights enable it to support portfolio companies effectively, enhancing their potential for success in the competitive healthcare market.
Historical Exits:
Active Portfolio Companies:
William Dai - Founding Managing Partner. William has extensive experience in venture capital and has led numerous successful investments in the healthcare sector.
Chaucer Shen - Managing Partner. Chaucer brings a wealth of knowledge in medical devices and has been instrumental in shaping the firm’s investment strategy.
Erik T. Engelson - Venture Partner. Erik has a strong background in biopharma and contributes to the firm’s due diligence processes.
Michael Wallace - Venture Partner. Michael specializes in healthcare technology and has a track record of successful exits in the sector.
Yajun Xu, Ph.D. - Senior Advisor. Yajun provides scientific expertise and insights into biopharmaceutical investments.
Nora Wu - Senior Advisor. Nora has a background in healthcare management and supports portfolio companies in operational strategies.
Mel Dong - Senior Advisor. Mel focuses on market analysis and helps startups navigate competitive landscapes.
Andy Weimin Dai - Senior Advisor. Andy has experience in venture capital and provides strategic guidance to portfolio companies.
Dr. Malcolm G. Munro - Senior Medical Advisor. Dr. Munro offers clinical insights and supports the firm’s investment decisions in medical devices.
Robert Kamen - Senior Advisor. Robert has a background in healthcare policy and assists in regulatory matters for portfolio companies.
Cindy Costello - Director of Finance & Administration. Cindy manages the firm’s financial operations and ensures compliance with industry standards.
Startups interested in pitching to ShangBay Capital should visit their website at shangbaycapital.com. It is important to include a comprehensive deck that outlines the business model, market opportunity, and team qualifications. The firm prefers warm introductions but also accepts direct submissions through their website. Response times may vary, but founders can expect feedback within a few weeks.
In 2023, ShangBay Capital has continued to expand its portfolio, adding several innovative healthcare startups. The firm has made notable investments in companies such as Corinth Medtech and Modular Surgical, which focus on advancing medical technologies.
ShangBay Capital has also highlighted its commitment to supporting healthcare innovation through various initiatives aimed at fostering collaboration among its portfolio companies. The firm remains active in the venture capital space, seeking new opportunities to invest in groundbreaking healthcare solutions.
What are ShangBay Capital's investment criteria?
ShangBay Capital focuses on investments in medical devices, biopharma, and healthcare technologies that address significant unmet clinical needs. The firm seeks early-stage opportunities that demonstrate clinical benefits.
How can startups apply or pitch to ShangBay Capital?
Startups can pitch to ShangBay Capital through their website at shangbaycapital.com. It is advisable to include a detailed business plan and information on the team and product.
What makes ShangBay Capital different from other venture firms?
ShangBay Capital emphasizes a collaborative approach with entrepreneurs, leveraging its extensive network to support product commercialization and startup growth. The firm has a deep understanding of market dynamics in the medical device industry.
What is the geographic scope of ShangBay Capital's investments?
The firm invests globally, with a strong focus on North America, allowing it to tap into diverse opportunities within the healthcare sector.
What is the typical check size for investments?
ShangBay Capital typically invests in early-stage companies, with check sizes that align with the needs of startups in the medical device and healthcare sectors.
What kind of post-investment involvement does ShangBay Capital have?
ShangBay Capital actively engages with its portfolio companies, providing operational support, mentorship, and access to its network to enhance commercialization efforts.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.